JPRN-jRCTb060190041暂停1 期
The study of intravenous administration of autologous cranial bone derived mesenchymal stem cells for moderate or severe cerebral infarction patients needed decompressive surgery
Mitsuhara Takafumi0 个研究点目标入组 6 人开始时间: 2020年3月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •Inclusion criteria at the time of first registration
- •1. First unilateral cerebral hemisphere infarction including the territory of middle cerebral artery
- •2. Cerebral infarction diagnosed by MRI (or CT), MRA (or CTA, cerebral angiography), electrocardiogram, chest lesion examination, etc.
- •3. Male or female between aged 20 or older and aged 85 or younger with 0 or 1 in modified Rankin Scale (mRS) before the onset
- •4. National Institutes of Health stroke scale (NIHSS) score >= 15
- •5. Decrease in the level of consciousness to a score of 1 or greater on item 1a of the NIHSS
- •6. Signs on CT of an infarct of at least 50% of the MCA territory, with or without additional infarction in the territory of the anterior or posterior cerebral artery on the same side, or
- •infarct volume >145 cm3 as shown on diffusion weighted MRI
- •7. Written informed consent by the patient or a legal representative after thorough understanding after having received sufficient explanation about this clinical study
- •Inclusion criteria at the time of Secondary registration
- •1. Informed consent by the patient or a legal representative from a free will after through understanding of this clinical study and sufficient understanding before cell transplantation
排除标准
- •Exclusion criteria at the time of first registrations
- •1. Out of standard treatment course in initial treatment of cerebral infarction until surgical decompression (severe hemorrhagic transformation of ischemic lesion, etc.)
- •2. Other serious illness with contraindication for surgical decompression
- •3. Positivity for hepatitis B virus, hepatitis C virus, HIV, or human T-cell lymphotropic virus type 1 at the initial screening
- •4. Significant risk for recurrence of cerebral infarction
- •5. Active or unstable intracranial lesions such as moyamoya disease, cerebral aneurysms at high risk of causing rupture or embolism, and severe intracranial hemorrhage.
- •6. Other serious comorbidity that could affect outcome (presence of a malignant tumor, uncontrolled proliferative diabetic retinopathy, etc.)
- •7. Serious allergy to any possible residues in the test product (e.g. any biomaterials used in manufacturing process, and gentamicin sulfate) or any agents used for the administration of the test product or any inspections during the trial
- •8. Significant abnormal laboratory tests (severe medical complications such as kidney dysfunction, liver dysfunction, etc.)
- •9. Participate in other clinical trial
- •10. Pregnant or possibly pregnant, lactating women, fertile women who are unable to practice contraception
- •11. Improper on the basis of the judgement by primary investigator or other investigators
- •Secondary registration selection exclusion criteria
- •1. Deep coma or coma evaluated by Japan Coma Scale (JCS; 300 or 200)
- •2. Out of the standard course of treatment for preceding cerebral infarction
- •3. There is a prospect that Autologous cranial bone derived mesenchymal stem cells that do not meet shipping criteria in post-production quality inspection not available
- •4. Improper on the basis of the judgement by primary investigator or other investigators
研究者
相似试验
已完成
1 期
The study of intravenous administration of autologous cranial bone derived mesenchymal stem cells for moderate or severe cerebral infarction patients needed decompressive surgerycerebral infarctionJPRN-UMIN000040503Hiroshima University Hospital3
已完成
2 期
VitiligoVitiligo.VitiligoIRCT201508201031N16Royan Institute300
尚未招募
不适用
Intravenous Administration of Autoserum-cultured Autologous Mesenchymal Stem Cells in Ischemic Stroke: A Single Center, Randomized, Open Label, Prospective, Phase 3 StudyDiseases of the nervous systemKCT0000574Samsung Medical Center63
已完成
不适用
Assessment on safety of intravenously administered trastuzumab with 100 ml saline solution in HER2 positive breast cancerBreast cancerJPRN-UMIN000006710Shiga University of Medical Science30
进行中（未招募）
1 期
Study with hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-controlled studyModerate-to-severe COVID-19 pneumoniaMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-003614-13-ITImmuneMed Inc.105